Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.49 |
| ▸ | BTK | Q06187 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 4/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3312900 | 0.85 | SMN1; SMN2 (0.49) | POLBSMN1; SMN2ALDH1A1TSHRKDM4E | |
| SCHEMBL3320407 | 0.83 | FAAH (0.50) | POLBSMN1; SMN2ALDH1A1TSHRKDM4E | |
| SCHEMBL3313906 | 0.83 | FAAH (0.50) | POLBSMN1; SMN2ALDH1A1TSHRKDM4E | |
| SCHEMBL3319485 | 0.83 | FAAH (0.50) | POLBSMN1; SMN2ALDH1A1TSHRKDM4E | |
| SCHEMBL3312696 | 0.83 | FAAH (0.50) | POLBSMN1; SMN2ALDH1A1TSHRKDM4E | |
| SCHEMBL3312538 | 0.83 | FAAH (0.50) | POLBSMN1; SMN2ALDH1A1TSHRKDM4E | |
| SCHEMBL3318340 | 0.83 | FAAH (0.50) | POLBSMN1; SMN2ALDH1A1TSHRKDM4E | |
| SCHEMBL3316341 | 0.83 | FAAH (0.50) | POLBSMN1; SMN2ALDH1A1TSHRKDM4E | |
| SCHEMBL8213702 | 0.80 | PDE4A (0.54) | POLBSMN1; SMN2ALDH1A1TSHRPRMT5 | |
| SCHEMBL8430557 | 0.79 | CNR1 (0.59) | ALDH1A1KDM4EBTKKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9718787-B2 | Poly (ADP-ribose) polymerase inhibitor | CHENGDU DI'AO PHARMACEUTICAL GROUP CO., LTD. (CN) | 2017-08-01 | — | — | US | disclosed |
| US-9278098-B2 | Substituted phthalazines for inducing insulin secretion and protecting beta-cells | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2016-03-08 | — | — | US | disclosed |
| US-20150368205-A1 | POLY (ADP-RIBOSE) POLYMERASE INHIBITOR | CHENGDU DI'AO PHARMACEUTICAL GROUP CO., LTD. (CN) | 2015-12-24 | — | — | US | disclosed |
| US-9187430-B2 | Poly (ADP-ribose) polymerase inhibitor | CHENGDU DI'AO PHARMACEUTICAL GROUP CO., LTD. (CN) | 2015-11-17 | — | — | US | disclosed |
| US-20150164892-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2015-06-18 | — | — | US | disclosed |
| EP-2132183-B1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | Univ Virginia Patent Found (US) | 2015-06-03 | — | — | EP | disclosed |
| EP-2132183-B1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | Univ Virginia Patent Found (US) | 2015-06-03 | — | — | EP | disclosed |
| US-20150051211-A1 | POLY (ADP-RIBOSE) POLYMERASE INHIBITOR | CHENGDU DI'AO PHARMACEUTICAL GROUP CO., LTD. (CN) | 2015-02-19 | — | — | US | disclosed |
| US-8871764-B2 | Lisofylline analogs and methods for use | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-20130137693-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2013-05-30 | — | — | US | disclosed |
| US-20100105690-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2010-04-29 | — | — | US | disclosed |
| US-20100105690-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2010-04-29 | — | — | US | disclosed |
| US-20100105690-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2010-04-29 | — | — | US | disclosed |
| EP-2132183-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | University Of Virginia Patent Foundation (US) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008108842-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008108842-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2008-09-12 | — | — | WO | disclosed |
| EP-0542850-A1 | POST-PROCESSING STABILIZED PHOTOTHERMOGRAPHIC MATERIAL. | MINNESOTA MINING & MFG (US) | 1993-05-26 | — | — | EP | disclosed |
| WO-1992002852-A1 | POST-PROCESSING STABILIZED PHOTOTHERMOGRAPHIC EMULSIONS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1992-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150164892-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | IAPP, RNASE1, CTSA | POLB 2008/4885SMN1; SMN2 45/4885ALDH1A1 3961/4885 |
| US-20100105690-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | IAPP, RNASE1, CTSA | POLB 2224/4885SMN1; SMN2 50/4885ALDH1A1 4004/4885 |
| US-20150051211-A1 | POLY (ADP-RIBOSE) POLYMERASE INHIBITOR | PARP1, PARP2, PARP11 | POLB 17/4885SMN1; SMN2 1437/4885ALDH1A1 607/4885 |
| US-20130137693-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | IAPP, RNASE1, CTSA | POLB 2224/4885SMN1; SMN2 50/4885ALDH1A1 4004/4885 |
| US-20150368205-A1 | POLY (ADP-RIBOSE) POLYMERASE INHIBITOR | PARP1, PARP2, PARP11 | POLB 17/4885SMN1; SMN2 1437/4885ALDH1A1 607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.